Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.60 |
| ▸ | GSK3B | P49841 | 7/20 | 0.60 |
| ▸ | PIM1 | P11309 | 6/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904778 | 0.78 | PIM1 (0.52) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL30117688 | 0.76 | CLK1 (0.61) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL3799521 | 0.76 | CLK1 (0.61) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL3668053 | 0.75 | ROCK2 (1.00) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL18446454 | 0.74 | ROCK2 (0.64) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL25452209 | 0.74 | GSK3B (0.60) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL29354919 | 0.74 | ROCK2 (0.58) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL7716146 | 0.74 | ROCK2 (0.58) | ROCK2GSK3BPIM1AURKBJAK2 | |
| SCHEMBL18038314 | 0.72 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20658522 | 0.72 | TRPA1 (0.50) | ROCK2GSK3BPIM1AURKBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655662-B2 | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure | ALCON RESEARCH, LTD. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1962853-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | Alcon Research, Ltd. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007076360-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)- PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON RESEARCH, LTD. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149548-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)-PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149548-A1 | (INDAZOL-5-YL)-PYRAZINES AND (1,3-DIHYDRO-INDOL-2-ONE)-PYRAZINES FOR TREATING RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK1, ROCK2, CIT | ROCK2 2/4885GSK3B 1044/4885PIM1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.